Evidence map›Paper›PMID 34021311›Full record

ArticleRheumatology (Oxford, England)2022

Recombinant CD300c-Ig fusion protein attenuates collagen-induced arthritis in mice.

Haiyan Liu, Jin Zhao, Min Su, Xiaohong Tian, Laijun Lai

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in pharmacology · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Haiyan LiuShandong Provincial Hospital, Shandong First Medical University, Jinan, China.
Jin ZhaoDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Min SuDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.
Xiaohong TianDepartment of Tissue Engineering, School of Fundamental Science, China Medical University, Shenyang, China.
Laijun LaiDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA.ORCID 0000-0002-4581-7642
University of Connecticut · USChina Medical University · CN

Funding

Transplantation of ESC-derived thymic epithelial progenitors expressing autoantigen(s) ameliorating experimental autoimmune encephalomyelitisR01AI123131 · NIAID · UNIVERSITY OF CONNECTICUT STORRS · PI LAI, LAIJUN · 2016 to 2020
$1.9M
The effects of BTNL2 on experimental autoimmune encephalomyelitisR21AI156779 · NIAID · UNIVERSITY OF CONNECTICUT STORRS · PI LAI, LAIJUN · 2021 to 2022
$443k
NIAID NIH HHS R01 AI123131NIAID NIH HHS R21 AI156779
6 · The paper itself

Abstract

objectivesRA is a chronic autoimmune disease characterized by joint inflammation and tissue destruction. Immune responses mediated by T cells and autoantibodies are known to play critical roles in RA. Collagen type II (CII)-induced arthritis (CIA) is a commonly used animal model of human RA. We have previously reported the identification of a new T cell inhibitory molecule CD300c. Here we investigate the ability of recombinant CD300c-IgG2a Fc (CD300c-Ig) fusion protein to prevent and treat CIA.

methodsMice were induced to develop CIA by CII and injected with CD300c-Ig or control Ig protein before or after CIA symptoms occur. The mice were examined for CIA clinical and pathological scores, and analysed for the expression of proinflammatory cytokines, the percentage and activation of CD4 T cells and regulatory T cells, CII-specific T cell proliferation and cytokine production, and CII-specific autoantibody production.

resultsIn a prevention model, CD300c-Ig significantly decreases CIA incidence, and reduces clinical and pathological arthritis scores. In the treatment model, CD300c-Ig ameliorates established CIA. The beneficial effects of CD300c-Ig are related to decreased expansion and activation of T cells in the spleen and reduced expression of proinflammatory cytokines in the joints. CD300c-Ig also inhibits CII-specific T cell proliferation and Th1 and Th17 cytokine production. In addition, CD300c-Ig treatment reduced the production of CII autoantibodies in the serum. Furthermore, CD300c-Ig inhibits the proliferation and activation of T cells from RA patients in vitro.

conclusionCD300c-Ig protein has the potential to be used in the treatment of patients with RA.

Indexed as

AnimalsArthritis, ExperimentalDisease Models, AnimalImmunoglobulin GMiceMice, Inbred DBAReceptors, ImmunologicRecombinant Fusion ProteinsT-Lymphocytes, RegulatoryCd300c protein, mouseImmunoglobulin GReceptors, ImmunologicRecombinant Fusion ProteinsautoantibodyCD300ccollagen-induced arthritiscytokineregulatory T cellsrheumatoid arthritisT cell inhibitory moleculeT cells

Identifiers

PMID34021311
PMCPMC8889306
OpenAlexW3161384404

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.